PHPhilip W. Hinds

Philip W. Hinds

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip W. Hinds has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis

    by Siobhan K. McRee, Abraham L. Bayer, Jodie Pietruska, Philip N. Tsichlis, Philip W. Hinds

    Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer due to its highly metastatic nature. Melanomas harboring oncogenic BRAFV600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain about whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and we investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT isoform-specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo, whereas AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby the inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that the elucidation of AKT2-specific functions in metastasis might inform therapeutic strategies to improve treatment options for melanoma patients.


  • Open Access

    AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis

    by Siobhan K. McRee, Abraham L. Bayer, Jodie Pietruska, Philip N. Tsichlis, Philip W. Hinds

    Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer, due to its highly metastatic nature. Melanomas harboring oncogenic BRAF V600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT-isoform specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo , while AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that elucidation of AKT2-specific functions in metastasis could inform therapeutic strategies to improve treatment options for melanoma patients. Graphical


  • Open Access

    AKT1 Is Required for a Complete Palbociclib-Induced Senescence Phenotype in BRAF-V600E-Driven Human Melanoma

    by Abraham L. Bayer, Jodie Pietruska, Jaymes Farrell, Siobhan McRee, Pilar Alcaide, Philip W. Hinds

    Cellular senescence is a carefully regulated process of proliferative arrest accompanied by functional and morphologic changes. Senescence allows damaged cells to avoid neoplastic proliferation; however, the induction of the senescence-associated secretory phenotype (SASP) can promote tumor growth. The complexity of senescence may limit the efficacy of anti-neoplastic agents, such as CDK4/6 inhibitors (Cdk4/6i), that induce a senescence-like state in tumor cells. The AKT kinase family, which contains three isoforms that play both unique and redundant roles in cancer progression, is commonly hyperactive in many cancers including melanoma and has been implicated in the regulation of senescence. To interrogate the role of AKT isoforms in Cdk4/6i-induced cellular senescence, we generated isoform-specific AKT knockout human melanoma cell lines. We found that the CDK4/6i Palbociclib induced a form of senescence in these cells that was dependent on AKT1. We then evaluated the activity of the cGAS-STING pathway, recently implicated in cellular senescence, finding that cGAS-STING function was dependent on AKT1, and pharmacologic inhibition of cGAS had little effect on senescence. However, we found SASP factors to require NF-κB function, in part dependent on a stimulatory phosphorylation of IKKα by AKT1. In summary, we provide the first evidence of a novel, isoform-specific role for AKT1 in therapy-induced senescence in human melanoma cells acting through NF-κB but independent of cGAS.


  • Open Access

    AKT1 is Required for a Complete Palbociclib-induced Senescence Phenotype in BRAF-V600E-Driven Human Melanoma

    by Abraham L. Bayer, Jodie Pietruska, Jaymes Farrell, Siobhan McRee, Pilar Alcaide, Philip W. Hinds

    Cellular senescence is a carefully regulated process of proliferative arrest accompanied by numerous functional and morphologic changes. Senescence allows damaged cells to avoid neoplastic proliferation, however induction of the senescence-associated secretory phenotype (SASP) can promote tumor growth. The complexity of the senescence response may limit the efficacy of anti-neoplastic agents, such as CDK4/6 inhibitors (Cdk4/6i), that induce a senescence-like, non-proliferative state in tumor cells. The AKT kinase family plays an important role in cellular growth and division, and is commonly hyperactive in many cancers including melanoma. AKT activity has also been implicated in regulation of senescence. The three AKT isoforms play both redundant and unique roles in tumorigenesis and cancer progression. To interrogate the role of AKT isoforms in the induction of cellular senescence by Cdk4/6i, we generated isoform specific AKT knockout human BRAF-V600E mutated melanoma cell lines. We found that the CDK4/6i Palbociclib induced a form of senescence in these cells that was dependent on AKT1. As a potential mechanism, we evaluated the activity of the cGAS-STING pathway, recently implicated in cellular senescence. While we showed cGAS-STING function to be dependent on AKT1, pharmacologic inhibition of either cGAS or STING had little effect on senescence. However, we found SASP factors to require NF-kB function, in part dependent on a stimulatory phosphorylation of IKKα by AKT1 previously reported in other models. In summary, we provide the first evidence of a novel, isoform specific role for AKT1 in therapy-induced senescence in human melanoma cells acting through NF-kB but independent of cGAS-STING.

  • Open Access

    A paean to Arnie Levine on the occasion of his 80th birthday

    by Philip W Hinds

    It is an honor and a privilege to have received PhD-level training in the molecular basis of tumorigenesis from Arnie Levine and to have received advice and support from him as a colleague in the decades that followed. I and numerous others who have been directly and indirectly intellectually nurtured by Arnie owe much of our success in biomedical research to his selfless sharing of his keen scientific insight, and the field of cancer therapeutics is enriched overall by the contributions his lab and ‘progeny’ have made over the course of his career. I first met Arnie in the fall of 1985 as a first-year PhD candidate at Princeton. As a wide-eyed country boy (more or less) with newly minted BS and MS degrees in Biochemistry from the University of Maine, I found myself in quite a different world on Princeton’s verdant campus and shortly thereafter in the gleaming halls of the brand-new Lewis Thomas Laboratories (LTL), the building of which was undoubtedly a satisfying accomplishment for Arnie as the Chair of Molecular Biology. Charged with finding my first rotation laboratory, and not without considerable trepidation, I approached Arnie and others about my options and was immediately taken with Arnie’s warmth and excitement over the research in his lab. This led to my enthusiastic request to perform my rotation with his team (and this choice was perhaps also influenced by the fact that Mike Cole’s and Jim Broach’s labs were oversubscribed), even though I was at the time rather unsure of what a laboratory rotation really entailed.

  • Open Access

    Senescence and tumor suppression

    by Philip Hinds, Jodie Pietruska

    Cellular senescence has emerged as a potent tumor suppression mechanism that restrains proliferation of cells at risk for malignant transformation. Although senescent cells have permanently exited the cell cycle, their presence can have detrimental effects on the surrounding tissue, largely due to the development of the senescence-associated secretory phenotype (SASP). Here, we review the tumor-suppressive and tumor-promoting consequences of the senescence response, focusing on the SASP as a key mediator of this dichotomy. Accumulating evidence suggests that the persistence of senescent cells can exacerbate the development of a pro-inflammatory, immunosuppressive microenvironment that can favor tumorigenesis. Given that senescence of tumor and stromal cells is a frequent outcome of anti-cancer therapy, approaches that harness the growth inhibitory effects of senescence while limiting its detrimental effects are likely to have great clinical potential.


  • Abstract B07: Differential roles for AKT isoforms in BRAF mutant melanoma

    by Siobhan K. McRee, Jodie R. Pietruska, Elisabeth Dignan, Philip W. Hinds

    Despite recent advances, melanoma remains the deadliest form of skin cancer, and new therapeutic strategies are urgently needed. The MAP kinase (MAPK) and PI3K/AKT pathways are central to both disease progression and chemoresistance in melanoma, with dual targeting approaches yielding promising results that would benefit from increased target specificity and selectivity. The AKT family of serine/threonine kinases comprises three highly homologous and functionally distinct isoforms (AKT1, AKT2, and AKT3) that play unique roles in melanoma but have not yet been leveraged for isoform-specific targeting. Our lab has engineered a unique mouse model of melanoma, in which mutant BRAFV600E is constitutively targeted to mouse melanocytes, resulting in spontaneous malignant disease upon additional loss of tumor suppressor genes, and faithfully recapitulates the human disease. We have identified differential and dynamic activation of AKT isoforms in our mouse melanoma model, which supports the hypothesis that AKT isoforms may play both non-redundant and compensatory roles in melanoma progression. To systematically address this question, we have genetically ablated each AKT isoform individually in melanoma-prone mice in order to elucidate the individual and unique contribution of each isoform to melanoma progression. In parallel, we performed in vitro studies using shRNA mediated conditional knockdown of AKTs in a wide variety of human melanoma cell lines. Our results support an isoform-specific role for AKT1 in promoting melanoma cell proliferation, while AKT2 stimulates cell migration. Further studies utilizing the precision genome editing technology CRISPR/Cas9 allows us to interrogate the effects of AKT isoform specific knockout (KO) on in vivo tumor formation. This work moves toward establishing the contribution of AKT isoforms to tumor progression in melanoma, using both human melanoma cell lines and mouse models, to advance our understanding of the role of AKT in melanomagenesis. With AKT inhibitors in clinical trials for melanoma, our findings could yield novel therapeutic strategies and increase the efficiency of existing therapies to improve treatment options and outcome for this devastating disease. Citation Format: Siobhan K. McRee, Jodie R. Pietruska, Elisabeth Dignan, Philip W. Hinds. Differential roles for AKT isoforms in BRAF mutant melanoma. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B07.

  • Open Access

    Commentary on Alfred G. Knudson, Jr.: “Hereditary Cancer, Oncogenes, and Antioncogenes”

    by Philip W. Hinds

    Imagination is more important than knowledge. For knowledge is limited, whereas imagination embraces the entire world, stimulating progress, giving birth to evolution. It is, strictly speaking, a real factor in scientific research.

  • Open Access

    Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy

    by Sarah E Ballatori, Philip W Hinds

    Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, affecting ~560 young patients in the United States annually. The term OS describes a diverse array of subtypes with varying prognoses, but the majority of tumors are high grade and aggressive. Perhaps because the true etiology of these aggressive tumors remains unknown, advances in OS treatment have reached a discouraging plateau, with only incremental improvements over the past 40 years. Thus, research surrounding the pathogenesis of OS is essential, as it promises to unveil novel therapeutic targets that can attack tumor cells with greater specificity and lower toxicity. Among the candidate molecular targets in OS, the retinoblastoma (RB) pathway demonstrates the highest frequency of inactivation and thus represents a particularly promising avenue for molecular targeted therapy. This review examines the present thinking and practices in OS treatment and specifically highlights the relevance of the RB pathway in osteosarcomagenesis. Through further investigation into RB pathway-related novel therapeutic targets, we believe that a near-term breakthrough in improved OS prognosis is possible.


  • Abstract A19: Expression of BRAFV600E in melanocytes induces Schwannian differentiation in vivo

    by Jodie R. Pietruska, Chi Luo, Philip W. Hinds

    Transgenic mice expressing BRAFV600E targeted to melanocytes via the tyrosinase promoter display hyperpigmentation of the skin, ears, tail, and paws, as well as profound graying of the hair, benign melanocytic hyperplasias and a low frequency of spontaneous melanomas on a mixed genetic background. In order to investigate the underlying mechanism of BRAFV600E-induced alterations in skin and hair, mice were backcrossed extensively onto a C57BL/6 background. Backcrossed BRAFV600E mice retained the phenotype of mixed background transgenic animals with respect to skin hyperpigmentation as well as premature hair graying. Analysis of skin samples from mice of different ages revealed an accumulation and mislocalization of hyperproliferative melanocytes, suggesting a developmental defect in melanocyte homing to hair follicles in response to activated BRAF. Moreover, melanocytic lesions in the skin developed into benign tumors resembling nerve sheath tumors of Schwannian origin, presumably due to the phenotypic switching of melanocytes into Schwann cells in response to chronic BRAFV600E stimulation. These benign tumors seldom progressed to melanoma in the absence of Akt pathway activation. A role for Akt activation in repressing the Schwannian differentiation program is suggested, as treatment of melanoma-derived cell lines with the Akt inhibitor MK-2206 results in elevated expression of Schwannian lineage markers at the transcript level. Therefore, in addition to induction of oncogene-induced senescence, eliciting lineage-switching from melanocytes into Schwann cells in response to oncogenic BRAF represents a potential tumor suppression mechanism to protect melanocytes from transformation, and repression of this phenotypic switch via activation of the Akt pathway may facilitate the ability of BRAFV600E to drive melanomagenesis.